S-17092, a prolyl endopeptidase inhibitor, is in phase I investigations with Servier in France for its potential in cognition disorders. Prolyl endopeptidase is involved in the metabolic breakdown of a number of neuropeptide neurotransmitters in the brain, and so inhibiting the action of the enzyme increases the activity of these neuropeptides. This produces nootropic effects which make S-17092 a promising and novel treatment for neurodegenerative conditions such as Alzheimer's disease and Parkinson's disease.

TAPI-1, known in the earlier literature as just TAPI, is an inhibitor of tumor necrosis factor-alpha converting enzyme (TACE)/ADAM 17, that inhibits the cleavage of TNF-α, TNFRI (p60), and TNFRII (p80). It was shown on mice model, that administration of TAPI-1 to mice with skin fibrosis induced by daily BLM injections lead to the significant suppressed BLM-induced skin thickness and the number of myofibroblasts, thus was suggested, that targeting the TNFalpha converting enzyme might be a new type of therapy for patients with systemic sclerosis (SSc).

3-Methoxytyramine (3-MT) is a human trace amine that occurs as a metabolite of the neurotransmitter dopamine. It has been shown to act as an agonist of human TAAR1, and an inhibitor of mitochondrial respiration. 3-MT has garnered research interest for its potential links and implications to Parkinson's disease and other Neurological disorders.

MLN120B is a potent and selective inhibitor of IKK-beta, which competes with ATP at the ATP-binding site. MLN120B has been shown to be a promising treatment in preclinical models of rheumatoid arthritis, non-Hodgkin's lymphoma and multiple myeloma.